Syngene

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Syngene - overview

Established

1993

Location

Bangalore, -, India

Primary Industry

Biotechnology

About

Founded in 1993, Syngene International operates from Bangalore, India, offering comprehensive services in drug development. The company has not reported any significant pivots in its strategy or operations. In July 2023, Syngene International, a portfolio company of CDPQ, GIC, Abu Dhabi Investment Authority, Goldman Sachs AIMS Group, Monetary Authority of Singapore and Morgan Stanley Alternative Investment Partners, agreed to acquire Stelis Biopharma’s manufacturing unit from Stelis Biopharma Private Limited for INR 6. 17 billion.


Syngene International Limited specializes in providing comprehensive contract research, development, and manufacturing services tailored to the biopharma and pharmaceutical industries. Its primary offerings include integrated drug discovery and development solutions for large and small molecules. The company operates through its innovative platform, SynVent, which facilitates therapeutic discovery and aids clients in navigating complex disease areas. Syngene serves a global client base that includes leading pharmaceutical and biotech companies, particularly in North America, Europe, and Asia, addressing needs in therapeutic development, clinical trials, and commercialization support.


Current Investors

GIC, CDPQ, Morgan Stanley Investment Management

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals

Website

www.syngeneintl.com

Total Amount Raised

Subscriber access only

Syngene - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Add-on, Corporate Carve Out, Trade SaleCompletedStelis Biopharma’s manufacturing unit-
PIPECompletedSyngene-
Unspecified ExitCompletedSyngene-
IPOCompletedSyngene-
BuyoutCompletedSyngene-

Displaying 1 - 5 of 5

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.